No Detail Found!

Efficacy of cisplatin plus paclitaxel as chemotherapy in patients with cervical cancer after laparoscopic nerve-sparing extensive hysterectomy and its effect on immune function

Author(s)
Jianxin Zhang Department of Gynecology, Cangxian County Hospital,Cangzhou, Hebei,China
Chunyan Song Department of Internal Medicine, Cangxian County Hospital,Cangzhou, Hebei,China
Bingqin Liu Department of Gynecology, Cangxian County Hospital,Cangzhou, Hebei,China
Abstract
To investigate the value of cisplatin plus paclitaxel in patients with middle and advanced cervical cancer after laparoscopic nerve-sparing extensive hysterectomy and its effect on their T lymphocyte subsets. 44 patients with middle and advanced cervical cancer were randomly divided into the control group (n = 22) and the observation group (n = 22). Patients in the control group received nab-paclitaxel as chemotherapy, while patients in the observation group received cisplatin plus nab-paclitaxel as adjuvant therapy. The local recurrence and distant metastasis rates were statistically analyzed after 1 year of follow-up. The overall effective rate in the observation group was significantly higher than that in the control group (P<0.05). The serum levels of IL-4, IL-10 and TNF-a in the two groups were reduced markedly after treatment than before treatment (P<0.05) and the observation group was significantly lower than the control group (P<0.05). After treatment, the proportion of CD3+ and CD4+ cells increased, the proportion of CD8+ cells decreased more significantly than that in the control group (P<0.05). The combination of cisplatin and paclitaxel was demonstrated to have obviously synergistic and attenuated effects after middle and advanced cervical cancer surgery, optimize the efficacy, reduce adverse effects, and improve the body's immune function.
Publication Details
Page(s) 355-359
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: S1, Year: 2022

Request the full text from PASTIC

Keywords
middle and advanced stage, Cisplatin, T lymphocyte subsets, Paclitaxel, Cervical Cancer
References
Buyukkoroglu G,Şenel B,Yenilmez E .1974 .Vaginal suppositories with siRNA and paclitaxel-incorporated solid lipid nanoparticles for cervical cancer: Preparation and in vitro evaluation. Methods Mol Biol, : 303-328.
Heeren AM,van Luijk IF,Lakeman J .2019 .Neoadjuvant cisplatin and paclitaxel modulate tumorinfiltrating T cells in patients with cervical cancer. Cancer Immunol Immunother., 68(11) : 1759-1767.
Kumar L,Harish P,Malik PS .2018 .Chemotherapy and targeted therapy in the management of cervical cancer. Curr. Probl. Cancer, 42(2) : 120-128.
Li J,Chen L,Liu Q,Tang M,Wang Y,Yu J .2018 .Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel. Cancer Biol, 19(6) : 507-517.
Li J,Chen Q,Deng Z Q .2019 .KRT17 confers paclitaxel-induced resistance and migration to cervical cancer cells. Life Sci, 224 : 255-262.
Liu JJ,Ho JY,Lee HW .2019 .Inhibition of phosphatidylinositol 3-kinase (pi3k) signaling synergistically potentiates antitumor efficacy of paclitaxel and overcomes paclitaxel-mediated resistance in cervical cancer. Int. J. Mol. Sci, 20(14) : 3383.
Mao BD,Xu P,Xu P,Zhong Y,Ding WW,Meng QZ .2019 .LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. , 44(2) : 44.
Marquina G,Manzano A,Casado A .2018 .Targeted agents in cervical cancer: beyond bevacizumab. Curr. Oncol. Rep, 20(5) : 40.
Nakamura F,Seino M,Suzuki Y .2019 .Successful management of cutaneous lymphangitis carcinomatosa arising from cervical cancer with paclitaxel-cisplatin and bevacizumab combination therapy: A case report and review of the literature. J. Med. Case Rep, 13(1) : 328.
Qiu H,Li J,Liu Q,Tang M,Wang Y .2018 .Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle, 17(10) : 1235-1244.
Rosen VM,Guerra I,McCormack M .2017 .Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumabcontaining therapies in persistent, recurrent, or metastatic cervical cancer. Int. J. Gynecol Cancer, 27(6) : 1237-1246.
Seber S,Sirin DY,Yetisyigit T,Bilgen T .2020 .Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line. Niger J. Clin. Pract, 23(3) : 386-391.
Tewari KS,Sill MW,Penson RT .2017 .Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). , 390(10103) : 1654-1663.
Wang YT,Li B,Li XG,Ma SK,Zhang R,Wu LY .2019 .fficacy and side effect analysis of paclitaxel liposome for neoadjuvant chemotherapy in locally advanced cervical cancer. Zhonghua Fu Chan Ke Za Zhi., 54(9) : 588-594.
Wei Y,Pu X,Zhao L .2017 .Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review). Oncol. Rep, 37(6) : 3159-3166.
Yavas G,Yavas C,Sen E,Oner I,Celik C,Ata O C .2019 .Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer. Int. J. Gynecol Cancer, 29(1) : 42-47.
Yu J,Zhao Y,Liu C Y .2020 .Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo. Clin. Transl, 22(1) : 60-69.
Zagouri F,Korakiti AM,Zakopoulou R .2019 .Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. Cancer Treat Rev., 79 : 101885.
Zhang L,Zheng CY,Cao JH,Luo SL .2020 .Efficacy of paclitaxel, carboplatin and bevacizumab for cervical cancer: A protocol for systematic review and metaanalysis. Medicine (Baltimore), 99(24) : e20558.
0

Citations

0

Downloads

10

Views